Patient factors and costs associated with prophylactic neurokinin-1 receptor antagonist use among women with invasive breast cancer

Key Points

• To identify patient, clinical, and health care factors influencing the use and costs of neurokinin-1 receptor antagonists among women with invasive breast cancer.
• Analyzed patient demographics such as age, race, and ethnicity.
• Evaluated clinical factors including emetic risk.
• Assessed health care factors like insurance and health plan type.
• Compared total costs of neurokinin-1 receptor antagonists against other antiemetics.
• Mean total costs for NK1-RAs were significantly higher than for other antiemetics.
• Certain combinations of first- and second-generation 5HT3-RAs with or without steroids had different cost implications.
• Guideline-concordant use of NK1-RAs could lead to substantial cost savings for patients and insurance providers.

Abstract